GlassScriptPhysician profile
Vahid Yeganeh
NPI 1982064358
$1,201.66
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $535 · 2021: $407.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $207.99 | 2019-2020 | |
| Astellas Pharma US INC | $124.65 | 2019-2021 | |
| Amgen INC. | $84.74 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $74.98 | 2019 | |
| Allergan, INC. | $57.06 | 2020 | |
| Optinose US, INC. | $57.05 | 2020-2021 | |
| Abbvie INC. | $50.53 | 2021 | |
| Amarin Pharma, INC. | $45.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.08 | 2019 | |
| Genentech USA, INC. | $30.41 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $20.61 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.96 | 2021 | |
| Pfizer Pharmaceuticals LLC | $15.80 | 2019 | |
| Eisai INC. | $15.06 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.28 | 2019 | |
| Merck Sharp & Dohme LLC | $12.87 | 2020 | |
| Medtronic, INC. | $12.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahid Yeganeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.